This compound has a stronger human clinical evidence base than typical research peptides, but it still requires clinician oversight and approved-use context.
Overview
Tesamorelin (Egrifta) is a stabilized GHRH analog and one of the few growth-hormone-related peptides with FDA approval — specifically for reducing excess abdominal fat in people with HIV-associated lipodystrophy.
How It's Thought to Work
It stimulates the pituitary's release of growth hormone, which affects fat metabolism, notably visceral (abdominal) fat.
What the Research Says
Supported by human clinical trials for its approved indication; off-label discussion outpaces the approved evidence.
Regulatory & Legal Status
FDA-approved and prescription-only for its specific indication. Off-label and gray-market use is unapproved.
Safety Considerations
Has defined warnings and contraindications. Use only under a prescribing clinician.